Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Noboru Yamamoto; Koichi Goto; Makoto Nishio; Kenichi Chikamori; Toyoaki Hida; Makoto Maemondo; Nobuyuki Katakami; Toshiyuki Kozuki; Hiroshige Yoshioka; Takashi Seto; Kosei Tajima; Tomohide Tamura

doi:10.1007/s10147-016-1052-3

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Cited By ~ 1

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1039-0 ◽

2016 ◽

Vol 22 (1) ◽

pp. 70-78 ◽

Cited By ~ 2

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Download Full-text

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.187 ◽

2021 ◽

Vol 32 ◽

pp. S1456

Author(s):

B. Halmos ◽

P. Cobb ◽

M.L. Johnson ◽

L. Jain ◽

S.J. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

Lung Cancer ◽

10.1016/j.lungcan.2013.07.003 ◽

2013 ◽

Vol 82 (1) ◽

pp. 109-114 ◽

Cited By ~ 51

Author(s):

Koichi Goto ◽

Makoto Nishio ◽

Noboru Yamamoto ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Egfr Mutation ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Prospective Phase ◽

Epidermal Growth

Download Full-text

A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts

Annals of Oncology ◽

10.1093/annonc/mdx091.039 ◽

2017 ◽

Vol 28 ◽

pp. ii42-ii43

Author(s):

S. Thomas ◽

R.C. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdx386.009 ◽

2017 ◽

Vol 28 ◽

pp. v542 ◽

Cited By ~ 1

Author(s):

I. Okamoto ◽

H. Udagawa ◽

S. Kanda ◽

T.H. Han ◽

I. Lakatos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000273 ◽

2014 ◽

Vol 9 (10) ◽

pp. 1532-1539 ◽

Cited By ~ 23

Author(s):

D. Ross Camidge ◽

Eamon M. Berge ◽

Robert C. Doebele ◽

Marc S. Ballas ◽

Thierry Jahan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Lung Cancer Targets and Therapy ◽

10.2147/lctt.s142972 ◽

2017 ◽

Vol Volume 8 ◽

pp. 217-229

Author(s):

Wolfgang Schuette ◽

Claus-Peter Schneider ◽

Walburga Engel-Riedel ◽

Christian Schumann ◽

Martin Kohlhaeufl ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

MO01.29 Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1–Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.10.134 ◽

2021 ◽

Vol 16 (1) ◽

pp. S27-S28

Author(s):

M.-J. Ahn ◽

F. Barlesi ◽

E. Felip ◽

E. Garon ◽

C.M. Martin ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7588 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7588-7588 ◽

Cited By ~ 15

Author(s):

D. R. Camidge ◽

M. S. Ballas ◽

S. Dubey ◽

M. Haigentz ◽

P. J. Rosen ◽

...

Keyword(s):

Lung Cancer ◽

Human Monoclonal Antibody ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text